Polycystic ovary syndrome, a condition affecting more than 170 million people worldwide, has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) in a landmark global study. Experts say the change will reshape how the condition is diagnosed, treated and understood.
A condition that has shaped the health of millions — yet has long been defined too narrowly — just got a new name backed by the most comprehensive global consensus in its history.
Polycystic ovary syndrome, commonly known as PCOS, has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a landmark international study published May 12 in The Lancet. The change, developed through a global consensus effort involving thousands of patients and clinicians, acknowledges that the condition is far more than a gynecological disorder — it is a complex, multisystem disease affecting endocrine, metabolic, reproductive, dermatological and psychological health.
Why the Old Name Fell Short
For decades, clinicians and patients alike recognized the term “polycystic ovary syndrome” as misleading. Despite what the name implies, many people with the condition do not have ovarian cysts. That single misconception has had cascading consequences: delayed diagnoses, fragmented care, unaddressed cardiovascular and metabolic risks, and persistent stigma — particularly around fertility.
Melanie Cree, a pediatric endocrinologist at the University of Colorado Anschutz Medical Campus and one of only two U.S.-based pediatric endocrinologists involved in the international effort, spoke directly to the stakes of this change.
“Renaming this condition is more than semantics; it’s about finally recognizing the full reality of what patients experience,” Cree said in a news release. “For too long, the narrow definition of PCOS has overlooked its metabolic and hormonal complexity, leaving many patients undiagnosed or misunderstood.”
The new name is designed to correct those gaps. “Polyendocrine” captures the condition’s hormonal complexity across multiple glandular systems. “Metabolic” acknowledges its significant cardiovascular and metabolic dimensions, including insulin resistance and elevated risks for type 2 diabetes and heart disease. And “Ovarian” maintains recognition of the ovaries’ role without reducing the entire condition to a reproductive issue.
What Changes With PMOS
The renaming is not simply a rebranding exercise. According to the consensus study, the adoption of PMOS will trigger updates to clinical guidelines, medical school curricula and international disease classification systems — meaning the new terminology is expected to be implemented consistently across the globe.
“Language matters in medicine,” Cree added. “The previous name often led to misconceptions and stigma, particularly around fertility. This change helps shift the conversation toward overall health rather than a single aspect of the condition.”
Practically speaking, the shift to PMOS is expected to promote earlier and more accurate diagnosis by encouraging clinicians to look beyond reproductive symptoms. It also broadens the research lens, opening new avenues to study how the condition affects metabolic and systemic health over a patient’s lifetime.
Why This Matters for Young People
PCOS — now PMOS — is one of the most common hormonal conditions affecting people with ovaries, and it frequently emerges during adolescence and young adulthood. College-aged students may already be living with the condition, whether diagnosed or not. Many are told their symptoms are normal or are given only partial explanations that focus exclusively on menstrual irregularity or fertility concerns.
A more accurate name and updated clinical guidelines could mean that young people seeking care for fatigue, weight changes, skin issues, mood disorders or irregular cycles are evaluated more holistically — and connected to the right specialists sooner. It also means the condition is more likely to be taught accurately in health classes, pre-med programs and nursing schools going forward.
“What makes this effort especially powerful is that it reflects the voices of thousands of patients and clinicians from around the world,” added Cree. “This renaming sets the foundation for meaningful change, from medical education to clinical guidelines to public awareness, and ultimately, better outcomes for patient care.”
A Global Effort With Local Stakes
The consensus study represents one of the most coordinated efforts in recent endocrinology history. The fact that patient voices were formally integrated into the process marks a shift in how the medical community approaches disease classification — not just as a scientific exercise, but as one with real human consequences.
For the more than 170 million people worldwide who live with this condition, the name change signals something that goes beyond terminology: recognition that their full experience has finally been seen.
Source: University of Colorado Anschutz